相关实验视频

Updated: Jul 16, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

18 F-前列腺特异性膜抗原正子发射断层扫描/淋巴结分期的计算机断层扫描中等/高风险前列腺癌:一个系统的审查和元分析

Zhengtong Lv^1,2, Liuqi Song³, Miao Wang¹

¹Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.

Chinese medical journal

|September 10, 2023

概括

18F-PSMA PET/CT在前列腺癌中对淋巴结分期具有很高的特异性,其诊断价值与68Ga-PSMA PET/CT相提并论. 这种成像技术有助于对中高风险患者的治疗计划.

科学领域:

核医学就是核医学.
在瘤学瘤学.
放射性药物放射性药物放射性药物

背景情况:

淋巴结分期对前列腺癌 (PCa) 治疗规划和监测至关重要.
18F-前列腺特异性膜抗原正子发射断层扫描/计算机断层扫描 (18F-PSMA PET/CT) 与68Ga-PSMA PET/CT相比,具有潜在的优势.
18F-PSMA PET/CT用于淋巴结分期的诊断实用性需要进一步研究.

研究的目的:

评估18F-PSMA PET/CT对中高风险前列腺癌患者淋巴结分期的诊断性能.
将18F-PSMA PET/CT的诊断疗效与现有方法进行比较.

主要方法:

通过使用EMBASE,PubMed,Cochrane图书馆和Web of Science数据库的数据进行了系统的元分析,数据库的时间为2022年10月1日.
搜索术语包括"前列腺癌"",18F"",淋巴结"",PSMA"和"PET/CT".
诊断准确度指标,如灵敏度,特异性,PLR,NLR,DOR和AUC,使用Stata 17软件进行计算.

主要成果:

分析包括8项诊断测试,包括734个样本和6346个淋巴结.
在患者水平上,18个F-PSMA PET/CT显示灵敏度为0.57和特异性为0.95 (AUC为0.94).
在病变水平上,灵敏度为0.40,特异性为0.99 (AUC为0.86),表明特异性高,但灵敏度中等.

结论:

在中高风险前列腺癌中,18 F-PSMA PET/CT对淋巴结分期具有中度敏感性和高特异性.
18F-PSMA PET/CT的诊断性能与68Ga-PSMA PET/CT的诊断性能相当.
这种成像模式对于精确的淋巴结分期在前列腺癌管理中是有价值的.

更多相关视频

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET